Literature DB >> 7142238

Osteotomy of the fusion mass in scoliosis.

Y Floman, J N Penny, L J Micheli, E J Riseborough, J E Hall.   

Abstract

The value of an osteotomy of the fusion mass in attaining realignment of the spine when a lateral shift of the trunk over the pelvis has developed in the frontal plane was studied in fifty-five patients. All had had a previously fused but progressive spinal deformity. The indications for osteotomy were progression of the curve, imbalance of the trunk, pain, deteriorating cardiopulmonary function, or pseudarthrosis, or a combination of these conditions. Twenty-one patients had idiopathic scoliosis; fourteen, congenital scoliosis; ten, paralytic scoliosis; four, myelodysplastic scoliosis; and six had scoliosis secondary to miscellaneous conditions. A total of 154 osteotomies of the fusion mass, or 2.8 osteotomies per patient, were performed. Nine patients underwent an anterior spinal osteotomy or wedge resection as well. Most had a two-stage procedure which consisted of a posterior osteotomy, halo-femoral traction, and a posterior re-fusion with Harrington instrumentation two weeks later. At an average follow-up of thirty-two months, it was found that osteotomy of the fusion mass enabled the surgeon to realign the trunk over the pelvis and to correct pelvis obliquity, but correction of the angular deformity was only secondary. Although the rate of complications was high (51 per cent, including one postoperative death), osteotomy of the fusion mass and re-fusion may be indicated in a patient with a previously fused but progressively unbalanced, painful deformity of the spine.

Entities:  

Mesh:

Year:  1982        PMID: 7142238

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  8 in total

1.  The Surgical Overcorrection of Lenke Type 1 Deformities with Selective Fusion Segments: What Happens to the Coronal Balance?

Authors:  Yunus Atici; Sinan Erdogan; Yunus Emre Akman; Murat Mert; Engin Carkci; Tolga Tuzuner
Journal:  Korean J Spine       Date:  2016-09-30

Review 2.  Frontal and sagittal imbalance in patients with adolescent idiopathic deformity.

Authors:  Ozren Kubat; Dror Ovadia
Journal:  Ann Transl Med       Date:  2020-01

3.  The use of fusion mass screws in revision spinal deformity surgery.

Authors:  Stephen J Lewis; Ranganathan Arun; Andrew Bodrogi; David E Lebel; Sofia P Magana; Taylor E Dear; Chris Witiw
Journal:  Eur Spine J       Date:  2013-06-07       Impact factor: 3.134

4.  Postoperative trunk shift in Lenke 1 and 2 curves: how common is it? and analysis of risk factors.

Authors:  Per D Trobisch; Amer F Samdani; Joshua M Pahys; Patrick J Cahill
Journal:  Eur Spine J       Date:  2011-05-01       Impact factor: 3.134

5.  Thoracic pedicle subtraction osteotomy in the treatment of severe pediatric deformities.

Authors:  Georgios Bakaloudis; Francesco Lolli; Mario Di Silvestre; Tiziana Greggi; Stefano Astolfi; Konstantinos Martikos; Francesco Vommaro; Giovanni Barbanti-Brodano; Alfredo Cioni; Stefano Giacomini
Journal:  Eur Spine J       Date:  2011-04-06       Impact factor: 3.134

6.  Preventing Fusion Mass Shift Avoids Postoperative Distal Curve Adding-on in Adolescent Idiopathic Scoliosis.

Authors:  Hideki Shigematsu; Jason Pui Yin Cheung; Mauro Bruzzone; Hiroaki Matsumori; Kin-Cheung Mak; Dino Samartzis; Keith Dip Kei Luk
Journal:  Clin Orthop Relat Res       Date:  2017-01-03       Impact factor: 4.176

Review 7.  A comprehensive review of the diagnosis and management of congenital scoliosis.

Authors:  Charles E Mackel; Ajit Jada; Amer F Samdani; James H Stephen; James T Bennett; Ali A Baaj; Steven W Hwang
Journal:  Childs Nerv Syst       Date:  2018-08-04       Impact factor: 1.475

8.  Comparison of effectiveness of Halo-femoral traction after anterior spinal release in severe idiopathic and congenital scoliosis: a retrospective study.

Authors:  Yong Qiu; Zhen Liu; Feng Zhu; Bin Wang; Yang Yu; Zezhang Zhu; Bangping Qian; Weiwei Ma
Journal:  J Orthop Surg Res       Date:  2007-11-30       Impact factor: 2.359

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.